New ways to boost myelin repair by targeting TGFβ1 signals in brain stem cells
Novel Modulators of TGFß1 signaling in regulation of remyelination by neural stem cells
This work explores whether changing TGFβ1 signaling can help brain stem cells rebuild myelin for people with demyelinating conditions like multiple sclerosis.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Georgia NIH-funded |
| Lab location | 1 site (Athens, United States) |
| Project ID | NIH-11237595 on NIH RePORTER |
What this research studies
Researchers are studying a group of adult neural stem cells that can become the cells that remyelinate damaged nerves. By comparing gene activity with and without the regulator Gli1, they found the TGFβ1 signaling pathway as a key controller of this repair process. Using bioinformatics and lab models of demyelination, they will test molecules and modifiers of TGFβ1 signaling to see whether stem cell recruitment and differentiation into myelin-making cells improve. The ultimate goal is to identify targets that could lead to therapies helping people with MS and similar diseases regain protective myelin.
Who could benefit from this research
Good fit: Adults with demyelinating disorders such as multiple sclerosis who are interested in remyelination-focused therapies would be the most directly relevant group.
Not a fit: People whose neurological problems are not caused by demyelination, those with advanced irreversible axonal loss, or children under 21 are less likely to benefit from these remyelination-specific approaches.
Why it matters
Potential benefit: If successful, this could point to new treatments that stimulate the brain's own stem cells to repair myelin and reduce nerve damage in diseases like multiple sclerosis.
How similar studies have performed: Related approaches have shown promise in animal and laboratory studies but so far have not produced approved remyelination treatments for people.
Where this research is happening
Athens, United States
- University of Georgia — Athens, United States (Active)
Researchers
- Principal investigator: Samanta, Jayshree — University of Georgia
- Study coordinator: Samanta, Jayshree
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.